TrialFrontiers in immunology2021

SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.

Katja G Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.